GlassScriptPhysician profile
Jamie L Moore
NPI 1952962664
$8,867.65
in general payments reported to CMS, 2019-2025
28 companies · $3,530 in 2025
The $3,530 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $253 · 2023: $2,102 · 2024: $2,984 · 2025: $3,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,615.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,130.93 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $988.89 | 2022-2025 | Caplyta |
| Abbvie INC. | $817.64 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $741.50 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $718.11 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $547.11 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $501.51 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $439.18 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $436.88 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $353.15 | 2022-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $286.12 | 2023-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $267.24 | 2023-2025 | Auvelity |
| Indivior INC. | $244.41 | 2023-2025 | Sublocade, Perseris |
| Vanda Pharmaceuticals INC. | $204.04 | 2025 | Fanapt |
| Almatica Pharma LLC | $174.66 | 2022-2025 | Loreev Xr, Sertraline Hcl |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $167.30 | 2023-2025 | Xelstrym, Secuado |
| Tris Pharma INC | $166.98 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Neos Therapeutics, LP | $116.56 | 2022-2023 | Adzenys Xr-Odt |
| Janssen Scientific Affairs, LLC | $115.20 | 2024-2025 | Invega Trinza, Invega Sustenna |
| Vertical Pharmaceuticals, LLC | $79.61 | 2024-2025 | Relexxii |
| Idorsia Pharmaceuticals US INC | $70.02 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $64.82 | 2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $60.88 | 2023-2025 | Trintellix |
| Sage Therapeutics, LLC | $53.00 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $49.04 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $33.69 | 2023 | Methylphenidate Hydrochloride |
| Braeburn INC. | $24.60 | 2024 | Brixadi |
| Supernus Pharmaceuticals, INC. | $14.58 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.